Our latest must-read developments


([link removed])


# December Update

Featured This Month:

* New funding for potential gene editing therapy
* Anti-infective enters Phase 2 trial
* New daily care check-in tool



Foundation Funds Development of Gene Editing Therapy

We have agreed to invest up to $15 million in
ReCode Therapeutics ([link removed])
to support the development of a gene editing therapy they are working on with Intellia Therapeutics that could be delivered into the lung cells of people with cystic fibrosis. While ReCode Therapeutics concentrates on the delivery system, Intellia Therapeutics is developing the gene editing therapy being delivered. The therapy is designed to target permanent or near-permanent correction of a specific nonsense mutation (also called a "stop" mutation) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Other rare mutations that are not eligible for CFTR modulators will be explored as the editing technology matures.


READ MORE ([link removed])




Phase 2 Trial Begins for Anti-Infective

Clarametyx Biosciences started the Phase 2a portion of a clinical trial of its novel therapy that aims to disrupt bacterial biofilms, which are protective structures that bacteria form to shield them from both the immune system and antibiotics. The drug could help people with CF with difficult-to-treat infections because it potentially makes bacteria more susceptible to antibiotics and the body's immune response. A Phase 1b trial of the drug in combination with inhaled Tobramycin did not show any safety issues in people with CF with Pseudomonas infections. Earlier this year, we agreed to
invest up to $5 million ([link removed])
in Clarametyx to support their Phase 1b/2a clinical trials. Use our
Clinical Trial Finder ([link removed])
to find enrolling clinical trials for anti-infectives.



CFTR2 Database Lists More Mutations

The CFTR2 database, which lists
CFTR variants ([link removed])
(or mutations), was recently updated to 1,085 CF-causing variants -- a 35% increase that now includes 367 variants not previously searchable on the
CFTR2 website ([link removed]). Most of these additional variants are rare, occurring in 1 to 3 individuals in the database. Additionally, 11 variants previously categorized as being of uncertain significance have been recategorized as:

* CF-causing (1)
* Non-CF causing (1)
* Variants of varying clinical consequence (9)





New Daily Care Check-In Tool

A study published in the
Journal of Cystic Fibrosis ([link removed])
showed that the CF Foundation's Daily Care Check-In tool was effective in helping people with CF identify factors that prevented them from doing daily care activities such as airway clearance. If you have concerns or face obstacles in doing therapies regularly, ask your care team if the Daily Care Check-In tool could help you identify barriers to sustaining your daily care.


READ THE FULL ARTICLE ([link removed])




Meet Other People in the CF Community

Want to talk to someone who also has cystic fibrosis or has children with CF, but don't know where to start? You can find support from other people who have had similar experiences as yours through CF Peer Connect. Complete
the application ([link removed])
or email noreferrer noopener (mailto:[email protected]) to get started and someone will follow up with you. The program also makes connections to Spanish speakers. To view the application in Spanish, click the language button on the top right of the page and select "Spanish" from the drop-down menu.



A New Era of CF Care

Recently published
guidance for CF clinical care ([link removed])
provides considerations and best practices for CF care and the number or type of health professionals needed to provide care as people with CF age and face a widening range of health needs. This interim guidance will continue to evolve as research is ongoing.


LEARN MORE ([link removed])




COST-CF survey results now available

Earlier this year, we asked you to share your experiences with health care costs and how those costs may impact you and your family. You generously shared your experiences, and
the results ([link removed])
showed that though each person's journey with cystic fibrosis can look different, the burden associated with the disease can be felt regardless of geography, income, and insurance coverage.


DISCOVER THE INSIGHTS ([link removed])




Stay connected with the CF Foundation via our social media channels or visit
cff.org/news ([link removed])
for the latest updates.


([link removed])
% link:[link removed] name="[link removed]" content="" %]
% link:[link removed] name="[link removed]" content="" %]
([link removed])



([link removed])


www.cff.org ([link removed])


Don't miss the latest information on CF Foundation research updates.
Sign up below:


SIGN UP FOR RESEARCH + CARE UPDATES ([link removed])


4550 Montgomery Avenue, Suite 1100N | Bethesda, MD 20814 US


DONATE ([link removed])




This email was sent to [email protected].
To continue receiving our emails, add us to your address book.

[Opt out]([link removed] "opt out of this mailing list") of this mailing list

Opt out ([link removed])
% link:[link removed] name="global opt out" content="" %]
of all CF Foundation emails